These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16546532)

  • 21. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A; Majkowska L
    Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P; Katavetin P
    N Engl J Med; 2009 Oct; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract]   [Full Text] [Related]  

  • 24. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

  • 26. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 27. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
    Duka I; Bakris G
    Pol Arch Med Wewn; 2009 Nov; 119(11):692-3. PubMed ID: 19920790
    [No Abstract]   [Full Text] [Related]  

  • 29. Renoprotective effects of renin-angiotensin-system inhibitors.
    de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME
    Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533
    [No Abstract]   [Full Text] [Related]  

  • 30. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

  • 31. Renin-Angiotensin system blockade for diabetic nephropathy prevention.
    Naviglio S; Pirozzi F
    Am J Cardiol; 2010 May; 105(10):1505. PubMed ID: 20451706
    [No Abstract]   [Full Text] [Related]  

  • 32. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAS blockade: new possibilities in the treatment of complications of diabetes.
    Ruilope L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i32-4:discussion i50. PubMed ID: 10956319
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimal inhibition of renin angiotensin system to salvage 'at risk' diabetic kidneys--emerging Indian evidence.
    Shah SN; Bansode BR; Kamath SA
    J Assoc Physicians India; 2004 Mar; 52():183-6. PubMed ID: 15636305
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment.
    Andersen NH; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):146-52. PubMed ID: 11881115
    [No Abstract]   [Full Text] [Related]  

  • 37. [Significance of RAAS inhibition in diabetic nephropathy].
    Tsuruya K; Toyonaga J
    Nihon Rinsho; 2012 Jul; 70 Suppl 5():411-8. PubMed ID: 23156430
    [No Abstract]   [Full Text] [Related]  

  • 38. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D deficiency: consequence or cause of CKD?
    de Boer IH; Thadhani R
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1844-6. PubMed ID: 24135217
    [No Abstract]   [Full Text] [Related]  

  • 40. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.